HPLC of Chimeric HLA-A*02:01 (mα3) &mB2M&TERT (ILAKFLHWL) Monomer 2054

SDS-PAGE gel of Chimeric HLA-A*02:01 (mα3) &mB2M&TERT (ILAKFLHWL) 2054

Chimeric HLA-A*02:01 (mα3) &mB2M&TERT (ILAKFLHWL) Monomer Protein 2054

$310.00 – $1,125.00

Summary

Expression: HEK293
Pure: Yes (HPLC)
Amino Acid Range: Gly25-Thr206(Human HLA-A*02:01 α1&α2) & Asp207-Glu299(Mouse H-2Ld α3), Ile21-Met119(mB2M) and ILAKFLHWL peptide

SKU: 2054parent Categories: proteins, Recombinant proteins Tag: active proteins

Weight	1 lbs
Dimensions	9 × 5 × 2 in
accession	A0A140T913(Human HLA-A*02:01 α1&α2)&P01897(Mouse HLd α3)&&P01887(Mouse B2M)&ILAKFLHWL
express system	HEK293
product tag	C-His
purity	> 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC
background	The human telomerase catalytic subunit human telomerase reverse transcriptase (hTERT) is expressed in many human cancer cells derived from multiple tissues, but infrequently in normal cells. Thus, hTERT is an attractive candidate target for tumor immunotherapy. hTERT:540–548 peptide (p540, ILAKFLHWL) has been identified as an effective HLA-A*0201-restricted T-cell epitope, an effective T-cell-based cancer treatment, including vaccines, against hTERT will likely require the identification of other MHC class I-restricted epitopes in this antigen.
molecular weight	The protein has a predicted MW of 48.00 kDa. Due to glycosylation, the protein migrates to 50-65 kDa based on Tris-Bis PAGE result.
available size	100 µg, 500 µg
endotoxin	Less than 1EU per μg by the LAL method.

Chimeric HLA-A*02:01 (mα3) &mB2M&TERT (ILAKFLHWL) Monomer Protein 2054

protein

Size and concentration 100, 500µg and liquid
Form Liquid
Storage Instructions Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Storage buffer Shipped with dry ice.
Purity > 95% as determined by Tris-Bis PAGE

target relevance
The human telomerase catalytic subunit human telomerase reverse transcriptase (hTERT) is expressed in many human cancer cells derived from multiple tissues, but infrequently in normal cells. Thus, hTERT is an attractive candidate target for tumor immunotherapy. hTERT:540â€“548 peptide (p540, ILAKFLHWL) has been identified as an effective HLA-A*0201-restricted T-cell epitope, an effective T-cell-based cancer treatment, including vaccines, against hTERT will likely require the identification of other MHC class I-restricted epitopes in this antigen.
Protein names Major histocompatibility complex, class I, A
Gene names HLA-A,HLA-A
Protein family MHC class I family
Mass 41449Da
Target Relevance information above includes information from UniProt accession: A0A140T913
The UniProt Consortium

HPLC of Chimeric HLA-A*02:01 (mα3) &mB2M&TERT (ILAKFLHWL) Monomer

The purity of Chimeric HLA-A*02:01 (mα3) &mB2M&TERT (ILAKFLHWL) Monomer is greater than 95% as determined by SEC-HPLC.

SDS-PAGE gel of Chimeric HLA-A*02:01 (mα3) &mB2M&TERT (ILAKFLHWL)

Chimeric HLA-A*02:01 (mα3) &mB2M&TERT (ILAKFLHWL) Monomer on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

Publications

pmid	title	authors	citation
We haven't added any publications to our database yet.

Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.